U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H28F2N6O4S
Molecular Weight 522.57
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TICAGRELOR

SMILES

CCCSc1nc(c2c(n1)n([C@]3([H])C[C@@]([H])([C@]([H])([C@@]3([H])O)O)OCCO)nn2)N[C@]4([H])C[C@@]4([H])c5ccc(c(c5)F)F

InChI

InChIKey=OEKWJQXRCDYSHL-FNOIDJSQSA-N
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500123240.pdf; http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002303/WC500100562.pdf; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000PharmR.pdf

Ticagrelor (known trade names Brilinta, Brilique and Possia) is a P2Y12 platelet inhibitor. Brilinta has been approved by the US Food and Drug administration (FDA) in 2011 and is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. Brilinta also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent. In vitro metabolism studies demonstrate that ticagrelor and its major active metabolite are weak inhibitors of CYP3A4, potential activators of CYP3A5 and inhibitors of the P-gp transporter. Most common adverse reactions are bleeding 12% and dyspnea 14%.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
BRILINTA

Approved Use

Indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. Reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.

Launch Date

1311120000000
Secondary
BRILINTA

Approved Use

Indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. Reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.

Launch Date

1311120000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1583 ng/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TICAGRELOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1208 ng/mL
270 mg single, oral
dose: 270 mg
route of administration: oral
experiment type: single
co-administered:
TICAGRELOR plasma
Homo sapiens
1208 ng/mL
360 mg single, oral
dose: 360 mg
route of administration: oral
experiment type: single
co-administered:
TICAGRELOR plasma
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10160 ng × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TICAGRELOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12379 ng*h/mL
270 mg single, oral
dose: 270 mg
route of administration: oral
experiment type: single
co-administered:
TICAGRELOR plasma
Homo sapiens
12381 ng*h/mL
360 mg single, oral
dose: 360 mg
route of administration: oral
experiment type: single
co-administered:
TICAGRELOR plasma
Homo sapiens
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TICAGRELOR plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TICAGRELOR plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1260 mg single, oral
Highest studied dose
healthy
DLT: Gastrointestinal disorder NOS, Sinus arrest...
Dose limiting toxicities:
Gastrointestinal disorder NOS (50%)
Sinus arrest (serious, 16.7%)
High grade atrioventricular block (serious, 16.7%)
Ventricular escape rhythm (serious, 16.7%)
Sources:
900 mg single, oral
MTD
healthy
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Sources:
unhealthy
Disc. AE: Dyspnea...
AEs leading to
discontinuation/dose reduction:
Dyspnea (0.9%)
Sources:
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Sources:
unhealthy
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (grade 3-5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal disorder NOS 50%
DLT
1260 mg single, oral
Highest studied dose
healthy
High grade atrioventricular block serious, 16.7%
DLT
1260 mg single, oral
Highest studied dose
healthy
Sinus arrest serious, 16.7%
DLT
1260 mg single, oral
Highest studied dose
healthy
Ventricular escape rhythm serious, 16.7%
DLT
1260 mg single, oral
Highest studied dose
healthy
Dyspnea 0.9%
Disc. AE
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Sources:
unhealthy
Bleeding grade 3-5
Disc. AE
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Sources:
unhealthy
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
likely
likely
likely
moderate [IC50 10.5 uM]
moderate [IC50 11.7 uM]
moderate [IC50 26.7 uM]
moderate [IC50 33 uM]
moderate [IC50 43 uM]
moderate [IC50 6.9 uM]
no (co-administration study)
Comment: Human liver microsomes, dicrofenac (substrate); Co-administration of ticagrelor (180 mg BID x 9 days) did not alter the systemic exposure of tolbutamide (500 mg QD on Day 5, CYP2C9 substrate) (GM ratio of AUCinf and Cmax were 103%, 110%, while 4-OH tolbutamide AUCinf GM ratio and Cmax GM ratio were 94% and 90%).
Page: 9-11
moderate [IC50 7.6 uM]
moderate [IC50 8.2 uM]
yes (co-administration study)
Comment: Human liver microsomes, midazolam (4-hydroxylation, substrate), no time-dependent inhibition; Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day1, 180 mg BID on Days 2-7) significantly increased simvastatin (80 mg on Day 5, CYP3A4/5 substrate) AUCinf by 56% and Cmax 81%, and simvastatin acid AUCinf by 52% and Cmax by 64%. Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day1, 180 mg BID on Days 2-7) significantly reduced oral midazolam (7.5 mg AM on Days 1 & 7) AUCinf by 10%, and 4’-OH-midazolam by 42%. Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day 1, 180 mg BID on Days 2-7) does not alter the systemic exposure of IV midazolam (2.5 mg IV over 2 min AM on Days 1 & 7) and significantly reduced 4’-OH- midazolam systemic exposure by ~ 23%.
Page: 9-12, 60-61, 66-67, (PMDA) 130
no [IC50 40 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
weak (co-administration study)
Comment: Human liver microsomes, midazolam (1-hydroxylation, substrate), midazolam 1-hydroxylation was activated in the presence of Cyt-b5 by 144.9% (CYP3A4 (cDNA expressed enzyme):Cyp-b5 = 1: 3 + 5.56 mcM ticagrelor), no time-dependent inhibition; Inhibited testosterone intrinsic clearance (IC50 = 23 mcM, pooled human liver microsomes (33 male and female donors); Co-administration of ticagrelor (270 mg AM + 90 mg PM on Day 1, 90 mg BID on Days 2-7) significantly increased atorvastatin (80 mg QD on Day 5) AUCinf 36% and Cmax 23%, atorvastatin lactone AUCinf 32% and Cmax 39%, s 2-OH atorvastatin AUCinf 33% and Cmax 13%, and 4-OH atorvastatin AUCinf 67% and Cmax 55%. Co-administration of ticagrelor (90 mg BID x 21 days) significantly increased ethinyl estradiol AUCinf, Cmax, and Cmin by 20%, 30.6%, and 20.2%, respectively. Co-administration of ticagrelor does not alter the systemic exposure of levonorgestrel. Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day1, 180 mg BID on Days 2-7) significantly reduced oral midazolam (7.5 mg AM on Days 1 & 7) AUCinf by 10%, but did not alter 1’-OH- midazolam AUC. Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day 1, 180 mg BID on Days 2-7) did not alter the systemic exposure of IV midazolam (2.5 mg IV over 2 min AM on Days 1 & 7) and 1’-OH-midazolam.
Page: 9-12, 62-63, 64-65, 66-67 (PMDA) 124-125, 130
no
no
no
no
no
no
no
no
strong [Ki 13.4 uM]
strong [Ki 16.3 uM]
strong [Ki 4.9 uM]
strong
weak
weak
yes [IC50 0.759 uM]
yes [IC50 1 uM]
yes [IC50 10 uM]
yes [IC50 16.9 uM]
yes [IC50 19.2 uM]
yes [IC50 19.9 uM]
yes [IC50 7.8 uM]
yes (co-administration study)
Comment: MDR1-MDCK monolayer, H3-digoxin (5 mcM) as a substrate, Flux ratio = 19.5 (digoxin only), 3.1 (digoxin + 10 mcM Ticagrelor); Co-administration of ticagrelor (400 mg QD, Days 1-16) significantly increased digoxin (0.25 mg BID on Day 6, 0.25 mg QD on Days 7-14, P-gp substrate) AUC0-72, Css,max, and Css, min by 28%, 75% and 31%, respectively.
Page: 4-5, 58-59 (PMDA) 157
yes [IC50 9.9 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major [Km 11 uM]
yes (co-administration study)
Comment: Human liver microsomes (determination of CYPs) and human cDNA expressed emzymes (Km for AR-C124910XX formation), Km (AR-C124910XX, human liver microsomes) = 27 mcM; Km (AR-C133913XX formation) = 41 mcM; Co-administration of ketoconazole (200 mg BID for 10 days, CYP3A4 inhibitor) significantly increased ticagrelor (90 mg QD on Day 4) AUCinf by 7.32 fold and Cmax by 2.35 fold, and decreased AR-C124910XX AUCinf by 56% and Cmax by 89%. Co-administration of diltiazem (240 mg QD x 14 days, moderate CYP3A4 inhibitor) significantly increased ticagrelor (90 mg QD on Day 8) AUCinf by 2.74 fold and Cmax by 1.69, and decreased AR-C124910XX AUCinf by 13% and Cmax by 38%. Co-administration of rifampin (600 mg QD Days 4-17, strong CYP3A4/P-gp inducer) significantly decreased ticagrelor (180 mg QD Days 1 & 15) AUCinf by 86% and Cmax by 73%, and decreased AR-C124910XX AUCinf by 46% and did not affect Cmax.
Page: 123, (ClinPharm) 5-6, 43-44, 45-47, 47-49
no
no
no
no
no
no
yes [Km 5.36 uM]
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
ADP receptor antagonism: what's in the pipeline?
2007
Gateways to clinical trials.
2007 Jun
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
2007 Nov 1
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
2007 Nov 6
Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
2007 Oct
Dyspnoea and antiplatelet agents: revisited.
2007 Sep
Gateways to clinical trials.
2008 Mar
Test before you stop.
2009 Aug
[Anticoagulants of primary haemostasis].
2009 Aug
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
2009 Aug
Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.
2009 Dec
Ticagrelor versus clopidogrel in acute coronary syndromes.
2009 Dec 10
Ticagrelor versus clopidogrel in acute coronary syndromes.
2009 Dec 10
ACP Journal Club. Ticagrelor was more effective than clopidogrel, with no increase in major bleeding in acute coronary syndromes.
2009 Dec 15
New P2Y12 blockers.
2009 Jul
Future of oral antiplatelet therapy: four challenged hypotheses.
2009 Jun
HOTLINE I, PLATO favours ticagrelor over clopidogrel in ACS.
2009 Nov
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
2009 Nov
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
2009 Nov
[Ticagrelor versus clopidogrel in patients with acute coronary syndromes: results of the PLATO study].
2010
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
2010 Apr
[Update: oral platelet inhibitors in cardiology].
2010 Apr
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
2010 Apr
The PLATO trial: do you believe in magic?
2010 Apr
Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques.
2010 Apr 12
Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention.
2010 Aug
Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
2010 Feb
The year in cardiothoracic and vascular anesthesia: selected highlights from 2009.
2010 Feb
Limitations of current therapies to prevent thrombosis: a need for novel strategies.
2010 Feb
The TRITON versus PLATO trials: differences beyond platelet inhibition.
2010 Feb
Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease.
2010 Jan
Recent advances in cardiology.
2010 Jan
Emerging P2Y12 receptor antagonists: role in coronary artery disease.
2010 Jan
[Update on new antithrombotic treatments].
2010 Jan 20
PLATO study of ticagrelor versus clopidogrel in patients with high-risk acute coronary syndromes.
2010 Jul
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
2010 Jul
Examining biology and pharmacology-based hypotheses in the PLATO trial.
2010 Jul
The case for routine genotyping in dual-antiplatelet therapy.
2010 Jul 6
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.
2010 Mar
Advances in antiplatelet therapy for stroke prevention: the new P2Y12 antagonists.
2010 Mar
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
2010 Mar
The novel P2Y 12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats.
2010 Mar
Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
2010 Mar 16
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
2010 Mar 16
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.
2010 May
Advances in antiplatelet treatment for acute coronary syndromes.
2010 May
Forecasting drug utilization and expenditure in a metropolitan health region.
2010 May 17
The year in interventional cardiology.
2010 May 18
Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.
2010 May 7
State of the art of new P2Y12 antagonists.
2010 Oct
Patents

Patents

Sample Use Guides

Initiate treatment with 180 mg (two 90 mg tablets) oral loading dose. Continue treatment with 90 mg twice daily.
Route of Administration: Oral
In human liver microsomes, ticagrelor inhibited midazolam 4-hydroxylation with an IC50 of 8.2 uM. Evaluated in fresh human hepatocytes at concentration up to 20 uM, ticagrelor was not an inducer of CYP1A2 or CYP3A4.
Name Type Language
TICAGRELOR
DASH   EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BRILINTA
Brand Name English
1,2-CYCLOPENTANEDIOL, 3-(7-(((1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL)AMINO)-5-(PROPYLTHIO)-3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-3-YL)-5-(2-HYDROXYETHOXY)-, (1S,2S,3R,5S)-
Systematic Name English
TICAGRELOR [WHO-DD]
Common Name English
AZD-6140
Code English
TICAGRELOR [MI]
Common Name English
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYLAMINO)-5-(PROPYLTHIO)-3H-(1,2,3)TRIAZOLO(4,5-D)PYRIMIDIN-3-YL)-5-(2-HYDROXYETHOXY)CYCLOPENTANE-1,2-DIOL
Systematic Name English
POSSIA
Brand Name English
TICAGRELOR [EMA EPAR]
Common Name English
TICAGRELOR [EP MONOGRAPH]
Common Name English
TICAGRELOR [USAN]
Common Name English
TICAGRELOR [ORANGE BOOK]
Common Name English
TICAGRELOR [INN]
Common Name English
TICAGRELOR [USP-RS]
Common Name English
TICAGRELOR [MART.]
Common Name English
AZD6140
Code English
BRILIQUE
Brand Name English
AR-C126532XX
Code English
TICAGRELOR [VANDF]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS POSSIA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
EMA ASSESSMENT REPORTS BRILIQUE (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
WHO-ATC B01AC24
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
EMA ASSESSMENT REPORTS POSSIA (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
WHO-VATC QB01AC24
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
NCI_THESAURUS C80483
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
NDF-RT N0000182142
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
EMA ASSESSMENT REPORTS BRILIQUE (AUTHORIZED:ACUTE CORONARY SYNDROME)
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
LIVERTOX 961
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
Code System Code Type Description
MERCK INDEX
M10853
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C76404
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
DRUG CENTRAL
4184
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
RXCUI
1116632
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY RxNorm
MESH
C503700
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
INN
8772
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
LACTMED
Ticagrelor
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
CAS
274693-27-5
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
NDF-RT
N0000182141
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
ChEMBL
CHEMBL398435
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
NDF-RT
N0000190482
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY Phenylalanine Hydroxylase Activators [MoA]
PUBCHEM
9871419
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY P-Glycoprotein Inhibitors [MoA]
HSDB
8306
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
NDF-RT
N0000182143
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY P2Y12 Receptor Antagonists [MoA]
WIKIPEDIA
Ticagrelor
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
USP_CATALOG
1667177
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY USP-RS
DRUG BANK
DB08816
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
EVMPD
SUB30898
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
FDA UNII
GLH0314RVC
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
IUPHAR
1765
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY
NDF-RT
N0000190115
Created by admin on Fri Jun 25 21:08:05 UTC 2021 , Edited by admin on Fri Jun 25 21:08:05 UTC 2021
PRIMARY Cytochrome P450 3A5 Inhibitors [MoA]